Comparative Pharmacology
Head-to-head clinical analysis: CABAZITAXEL versus TAXOTERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CABAZITAXEL versus TAXOTERE.
CABAZITAXEL vs TAXOTERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Microtubule inhibitor. Binds to tubulin and promotes microtubule assembly while inhibiting disassembly, leading to mitotic arrest and cell death. Also inhibits tubulin deacetylation and has anti-angiogenic properties.
Taxotere (docetaxel) is a semisynthetic taxane that promotes microtubule assembly and inhibits depolymerization, leading to stabilization of microtubules and disruption of mitotic cell division. This results in cell cycle arrest at G2/M phase and apoptosis in cancer cells.
25 mg/m2 intravenously every 3 weeks in combination with oral prednisone 10 mg daily.
75 mg/m² intravenously over 1 hour every 3 weeks.
None Documented
None Documented
Clinical Note
moderateCabazitaxel + Verteporfin
"The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Verteporfin."
Clinical Note
moderateCabazitaxel + Digoxin
"Cabazitaxel may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCabazitaxel + Digitoxin
"Cabazitaxel may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCabazitaxel + Deslanoside
Terminal half-life approximately 95 h (range 77–120 h) in patients with normal hepatic function; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 11–13 hours, with a mean of 11.1 hours. This supports a 3-week dosing interval.
Primarily hepatobiliary (76% in feces as metabolites), renal (2-3% unchanged; 20% total in urine as metabolites).
Following hepatic metabolism, elimination is primarily via biliary/fecal excretion (approximately 75% of dose as metabolites and unchanged drug), with renal excretion accounting for about 10% (primarily as metabolites).
Category C
Category C
Taxane Antineoplastic
Taxane Antineoplastic
"Cabazitaxel may decrease the cardiotoxic activities of Deslanoside."